Objective  To analysis differences in differentially expressed microRNAs (miRNAs) between luminal and basal-like breast cancer, and to explore the relationship between the expression level and the prognosis of luminal and basal-like breast cancer.Methods  The miRNAs microarray datasets GSE81000 and GSE40267 which included the luminal and basal-like breast cancer patients were downloaded from the Gene Expression Omnibus (GEO). The GEO2R analysis tool was used to screen differentially expressed miRNAs in luminal and basal-like breast cancer patients. The target genes of differentially expressed miRNAs were predicted by mirDIP database. The differential expression miRNAs verification was performed on human breast cancer cell lines MCF-7 and MDA-MB-468 using quantitative real-time PCR. Finally, the relationship between the expression levels of miR-199a-5p and miR-199b-5p and the prognosis of luminal and basal-like breast cancer was analyzed by Kaplan Meier plotter online survival analysis. Results  There were a total of 35 differentially expressed miRNAs in luminal and basal-like breast cancer, of which 18 miRNAs were down-regulated and 17 miRNAs were up-regulated compared to luminal breast cancer. Target gene prediction results shows that were 4,180 potential target genes in these 35 differentially expressed miRNAs, among which 19 were the most related, and the corresponding differential miRNAs were miR-199a-5p and miR-199b-5p. Compared with luminal breast cancer, miR-199a-5p and miR-199b-5p were down regulated in basal-like breast cancer. Quantitative real-time PCR results showed that the expression levels of miR-199a-5p and miR-199b-5p in MCF-7 and MDA-MB-468 cells were consistent with the results of GEO2R analysis. The results of survival analysis showed that the low expression of miR-199a-5p and miR-199b-5p was associated with the decreased overall survival rate of patients with luminal A breast cancer. Conclusion  35 differentially expressed miRNAs in luminal and basal-like breast cancer were screened. Among them, miR-199a-5p and miR-199b-5p are related to the prognosis of breast cancer. These miRNAs are expected to become new therapeutic biomarkers.

1.Heer E, Harper A, Escandor N, et al. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study[J]. Lancet Glob Health, 2020, 8(8): e1027-e1037. DOI: 10.1016/S2214-109X(20) 30215-1.

2.International Agency for Research on Cancer. Latest global cancer data: cancer burden rises to 19.3 million new cases and 10.0 million cancer deaths in 2020[EB/OL]. [Access on 2020-12-15]. https://www.iarc.who.int/wp-content/uploads/2020/12/pr292_E.pdf.

3.Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): e279-e289. DOI: 10. 1016/S1470-2045(13)70567-9.

4.DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(6): 438-451. DOI: 10.3322/caac.21583.

5.Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797): 747-752. DOI: 10.1038/35021093.

6.Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes[J]. J Clin Oncol, 2009, 27(8): 1160-1167. DOI: 10.1200/JCO. 2008.18.1370.

7.Haibe-Kains B, Desmedt C, Loi S, et al. A three-gene model to robustly identify breast cancer molecular subtypes[J]. J Natl Cancer Inst, 2012, 104(4): 311-325. DOI: 10.1093/jnci/djr545.

8.张力文.基于分子分型的乳腺癌流行病学研究[D]. 天津医科大学, 2018. DOI: 10.27366/d.cnki.gtyku.2018.000 007. [Zhang LW. Epidemiological study of breast cancer based on molecular subtyping[D]. Tianjin medical university, 2018.]

9.李杰宝, 喻晓程, 田野. 乳腺癌分子分型与临床病理参数的关系及预后[J]. 中华实验外科杂志, 2018, 35(6): 1027-1029. DOI: 10.3760/cma.j.issn.1001- 9030.2018.06.010. [Li JB, Yu XC, Tian Y. Correlation between molecular subtypes, clinicopathological parameters and prognosis of breast cancer[J]. Chinese Journal of Experimental Surgery, 2018, 35(6): 1027-1029.]

10.O'Brien J, Hayder H, Zayed Y, et al. Overview of Microrna biogenesis, mechanisms of actions, and cir-culation[J]. Front Endocrinol (Lausanne), 2018, 9: 402. DOI: 10.3389/fendo.2018.00402.

11.Perri F, Longo F, Giuliano M, et al. Epigenetic control of gene expression: potential implications for cancer treatment[J]. Crit Rev Oncol Hematol, 2017, 111: 166-172. DOI: 10.1016/j.critrevonc.2017.01.020.

12.Shin VY, Siu JM, Cheuk I, et al. Circulating cell-free miRNAs as biomarker for triple-negative breast cancer[J]. Br J Cancer, 2015, 112(11): 1751-1759. DOI: 10.1038/bjc.2015.143.

13.Bockmeyer CL, Christgen M, Müller M, et al. MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes[J]. Breast Cancer Res Treat, 2011, 130(3): 735-745. DOI: 10.1007/s10549-010-1303-3.

14.Tokar T, Pastrello C, Rossos AE, et al. mirDIP 4.1-integrative database of human microRNA target predictions[J]. Nucleic Acids Res, 2018, 46(1): 360-370. DOI: 10.1093/nar/gkx1144.

15.Wesseling J, Tinterri C, Sapino A, et al. An international study comparing conventional versus mRNA level testing (Target Print) for ER, PR, and HER2 status of breast cancer[J]. Virchows Arch, 2016, 469(3): 297-304. DOI: 10.1007/s00428-016-1979-9.

16.Li L, Xiao B, Tong H, et al. Regulation of breast cancer tumorigenesis and metastasis by miRNAs[J]. Expert Rev Proteomics, 2012, 9(6): 615-625. DOI: 10.1586/epr.12.64.

17.王维君, 何科基, 那光玮, 等. microRNA的生物学功能及其在乳腺癌发生发展中的作用[J]. 甘肃医药, 2020, 39(5)：389-391. DOI: 10.15975/j. cnki.gsyy. 2020.05.002. [Wang WJ, He KJ, Na GW, et al. Biological function of microRNA and its role in the development of breast cancer[J]. Gansu Medical Journal, 2020, 39(5): 389-391.]

18.Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105(30): 10513-10518. DOI: 10.1073/pnas.0804549105.

19.Nassar FJ, Nasr R, Talhouk R. MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction[J]. Pharmacol Ther, 2017, 172: 34-49. DOI:   10.1016/j.pharmthera.2016.11.012.

20.翟丽敏, 杨硕, 李文通. miRNA-199a-5p通过SP1调节ERK5抑制乳腺癌MDA-MB-231细胞侵袭的机制[J].临床与实验病理学杂志, 2015, 31(9): 981-985. DOI: 10.13315/j.cnki.cjcep.2015.09.005. [Zhai LM, Yang S, Li WT. miRNA-199a-5p inhibit the invasion of MDA-MB-231 cells via regulating ERK5 through SP1 [J]. J Clin Exp Pathol, 2015, 31(9): 981-985.]  

21.Turashvili G, Lightbody ED, Tyryshkin K, et al. Novel prognostic and predictive microRNA targets for triple-negative breast cancer[J]. FASEB J, 2018, 32: 1-18. DOI: 10.1096/fj.201800120R.

22.Wu A, Chen Y, Liu Y, et al. miR-199b-5p inhibits triple negative breast cancer cell proliferation, migration and invasion by targeting DDR1[J]. Oncol Lett, 2018, 16(4): 4889-4896. DOI: 10.3892/ol.2018.9255.

23.Fang C, Wang FB, Li Y, et al. Down-regulation of miR-199b-5p is correlated with poor prognosis for breast cancer patients[J]. Biomed Pharmacotherapy, 2016, 84: 1189-1193. DOI: 10.1016/j.biopha.2016.10.006.

24.Temian DC, Pop LA, Irimie AI, et al. The epigenetics of triple-negative and basal-like breast cancer: current knowledge[J]. J Breast Cancer, 2018, 21(3): 233-243. DOI: 10.4048/jbc.2018.21.e41.

25.Li W, Wang H, Zhang J, et al. miR-199a-5p regulates β1 integrin through Ets-1 to suppress invasion in breast cancer[J]. Cancer Sci. 2016, 107(7): 916-923. DOI: 10.1111/cas.12952.

26.Lin X, Qiu W, Xiao Y, et al. MiR-199b-5p suppresses tumor angiogenesis mediated by vascular endo-thelial cells in breast cancer by targeting ALK1[J]. Front Genet, 2020, 10: 1397. DOI: 10.3389/fgene.2019.01397.